See other companies on Otta
Curebase
Decentralized clinical trials platform
- 101-200 employees
- Healthcare
- B2B
- Enterprise
- SaaS
- 335 S Van Ness Ave, San Francisco, CA 94103, USA
Jump to section
Company mission
To bring quality medical innovations to patients faster and improve human wellbeing through more efficient clinical studies.
243% employee growth in 12 months
Otta's take
Theo Margolius
COO of Otta
Curebase offers a decentralized clinical trial software which allows research to be carried out at a patient’s home with their own doctor, in an aim to expedite the trial phase of clinical research. While the pandemic itself cast a spotlight on the speed at which we can develop and trial effective medication, it also delayed a whole host of in-person trials for other treatments.
By decentralizing the trial process, Curebase helps patients fit trials into their daily life at home, which has two big payoffs. The first is that trials become faster, and the second is that it diversifies the patients themselves.
They’re not alone in their pursuit to improve clinical trials, with Unlearn.AI and Medable making waves. However, in an industry that's set to be worth $50 billion by 2026, Curebase has made a strong start and is used by the likes of Alira Health, Adaptive Biotechnologies, and Quit Genius.
Benefits
- 100% coverage for Medical / Dental / Vision
- 401k plan
- Flexible PTO
- A passionate team dedicated to making a positive impact
- Unlimited career growth opportunity
- 100% remote work
Funding (last 2 of 3 rounds)
May 2022
$40m
SERIES B
May 2021
$15m
SERIES A
$57.6m
Total funding
This company has top investors
Founders
Tom Lemberg
(CEO)Studied Computer Science at Harvard, and is a Y Combinator graduate. Interned in Software Development at Amazon, and was a Product Manager at Syapse.